Matthew J Martin

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 4

Top Topics

Emergency Department

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Top Venues

Cancer research communications

Clinical cancer research : an official journal of the American Association for Cancer Research

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Ursula Grazini, Aleksandra A Markovets, Lucy Ireland, Daniel O'Neill, Benjamin Phillips, Man Xu, Matthias Pfeifer, Tereza Vaclova, Matthew J Martin, Ludovic Bigot, Luc Friboulet, Ryan J Hartmaier, Maria Emanuela Cuomo, Simon T Barry, Paul D Smith, Nicolas Floc'h
Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven Non-Small-Cell-Lung-Cancer with PIK3CA/PTEN alterations. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Matthew J Martin, Nicolas Floc'h, Matthias Pfeifer, Steven Criscione, Oona Delpuech, Sladjana Gagrica, Yi Yao, Ultan McDermott, Paul D Smith
Pharmaceutical Reactivation of Attenuated Apoptotic Pathways Leads to Elimination of Osimertinib Drug-Tolerant Cells. Cancer research communications 2 (10) (2022)
Matthew J Martin, Nicolas Floc'h, Matthias Pfeifer, Steven Criscione, Oona Delpuech, Sladjana Gagrica, Yi Yao, Ultan McDermott, Paul D Smith
Pharmaceutical Reactivation of Attenuated Apoptotic Pathways Leads to Elimination of Osimertinib Drug-Tolerant Cells. Cancer research communications 2 (10) (2022)
Nicolas Floc'h, Sangbin Lim, Sue Bickerton, Afshan Ahmed, Jonathan Orme, Jelena Urosevic, Matthew J Martin, Darren A E Cross, Byoung Chul Cho, Paul D Smith
Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I. Molecular cancer therapeutics 19 (11) (2020)